FinancialContent is the trusted provider of stock market information to the media industry.
Pinpoint Genomics Announces Availability of its Pinpoint Dx Lung™ Assay

MOUNTAIN VIEW, Calif., Jan. 27, 2012 /PRNewswire/ -- Pinpoint Genomics, Inc.  announced the publication of key data relating to its Pinpoint Dx Lung Assay in the journal The Lancet, and the availability of its Pinpoint Dx Lung Assay to clinicians and patients exclusively through the company's laboratory in Mountain View, CA.

The report in The Lancet describes the development of the assay based on specimens from 361 patients who underwent surgery at the University of California, San Francisco (UCSF), as well as the results of the two largest independent, blinded studies to evaluate the clinical validity of a multi-gene molecular diagnostic assay for early stage lung cancer. The two validation studies, conducted by the Kaiser Permanente Division of Research and the China Clinical Trials Consortium, involved 433 patients from northern California and 1,006 patients from several leading cancer centers in China, respectively.

The Pinpoint Dx Lung assay is run on surgical specimens that undergo routine handling by pathology laboratories, making it immediately available to virtually all patients, and is offered through Pinpoint's Clinical Laboratory Improvement Amendment-certified laboratory.

For information on how to send a sample to the Pinpoint Genomics laboratory, visit the company's website at www.pinpoint, and click on "Order Test" and download the Test Order Form, which contains all of the information necessary for physicians to order the test. The test is currently not available in all states. For additional information or questions, physicians can call the laboratory at 888-279-5088.

About Pinpoint Genomics and the Pinpoint Dx Lung Assay

The Pinpoint Dx Lung Assay is a molecular diagnostic assay that differentiates between patients at high, intermediate or low risk of early death after surgery to remove a non-squamous, non-small cell lung cancer, the most common form of lung cancer, in patients with early stage disease.

Pinpoint Genomics, Inc. is a privately held cancer company focused on the development and commercialization of molecular assays and genomic-based clinical laboratory services to provide individualized information to patients and clinicians.  

Pinpoint Genomics is also developing additional assays for patients with lung and other cancers. For more information, please visit , or fax inquiries to (866) 714-9299.

The Pinpoint Genomics logo and Pinpoint Dx Lung Assay are trademarks of Pinpoint Genomics, Inc.


SOURCE Pinpoint Genomics, Inc.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here
Financial Widgets

Display market data, financial news or stock quotes - Learn More

Advertising Network

Advertise on FinancialContent's huge network - Learn More

Web Services

Power your internet and wireless applications - Learn More